Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Physics

Cancer Oncology

Medicine

Immunology

Internal Medicine

Show all topics

DOI

10.1200/jco.22.01725

License

CC-BY

Other Formats

PDF